Is LNSR or OBIO more profitable?

LENSAR has a net margin of 57.57% compared to Orchestra BioMed's net margin of -184.60%. Orchestra BioMed's return on equity of -149.61% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 57.57% -529.08% 50.03% Orchestra BioMed -184.60% -149.61% -54.15%

Is LNSR or OFIX more profitable?

LENSAR has a net margin of 57.57% compared to Orthofix Medical's net margin of -7.41%. Orthofix Medical's return on equity of -14.05% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 57.57% -529.08% 50.03% Orthofix Medical -7.41% -14.05% -7.17%

Which has better earnings & valuation, LNSR or MOBI?

LENSAR has higher revenue and earnings than Mobia Medical. LENSAR is trading at a lower price-to-earnings ratio than Mobia Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENSAR $58.44M 1.49 -$34.28M -$0.33 N/A Mobia Medical $32.04M 10.95 -$46.50M -$20.18 N/A

Is LNSR or MOBI more profitable?

LENSAR has a net margin of 57.57% compared to Mobia Medical's net margin of 0.00%. Mobia Medical's return on equity of 0.00% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 57.57% -529.08% 50.03% Mobia Medical N/A N/A N/A

Is CV or LNSR more profitable?

LENSAR has a net margin of 57.57% compared to CapsoVision's net margin of -214.74%. CapsoVision's return on equity of -177.85% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -214.74% -177.85% -135.07% LENSAR 57.57% -529.08% 50.03%

Is LNSR or RCEL more profitable?

LENSAR has a net margin of 57.57% compared to Avita Medical's net margin of -56.96%. Avita Medical's return on equity of 0.00% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 57.57% -529.08% 50.03% Avita Medical -56.96% N/A -78.53%

LENSAR (LNSR) Competitors

$7.07 -0.02 (-0.28%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.07 0.00 (0.00%)

As of 09/18/2026 04:10 PM Eastern

Compare

LNSR vs. OBIO, OFIX, MOBI, CV, and RCEL

Should you buy LENSAR stock or one of its competitors? LENSAR's main competitors and comparable companies include Orchestra BioMed (OBIO), Orthofix Medical (OFIX), Mobia Medical (MOBI), CapsoVision (CV), and Avita Medical (RCEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does LENSAR compare to Orchestra BioMed?

LENSAR (NASDAQ:LNSR) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

LENSAR presently has a consensus price target of $11.50, indicating a potential upside of 62.66%. Orchestra BioMed has a consensus price target of $13.17, indicating a potential upside of 116.56%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

LENSAR has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

LENSAR has a net margin of 57.57% compared to Orchestra BioMed's net margin of -184.60%. Orchestra BioMed's return on equity of -149.61% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	57.57%	-529.08%	50.03%
Orchestra BioMed	-184.60%	-149.61%	-54.15%

LENSAR has higher revenue and earnings than Orchestra BioMed. LENSAR is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.49	-$34.28M	-$0.33	N/A
Orchestra BioMed	$33.48M	10.91	-$52.70M	-$0.85	N/A

In the previous week, Orchestra BioMed had 6 more articles in the media than LENSAR. MarketBeat recorded 6 mentions for Orchestra BioMed and 0 mentions for LENSAR. Orchestra BioMed's average media sentiment score of 0.35 beat LENSAR's score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company	Overall Sentiment
LENSAR	Neutral
Orchestra BioMed	Neutral

40.2% of LENSAR shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 65.8% of LENSAR shares are owned by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Orchestra BioMed beats LENSAR on 9 of the 16 factors compared between the two stocks.

How does LENSAR compare to Orthofix Medical?

LENSAR (NASDAQ:LNSR) and Orthofix Medical (NASDAQ:OFIX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

LENSAR has a net margin of 57.57% compared to Orthofix Medical's net margin of -7.41%. Orthofix Medical's return on equity of -14.05% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	57.57%	-529.08%	50.03%
Orthofix Medical	-7.41%	-14.05%	-7.17%

40.2% of LENSAR shares are owned by institutional investors. Comparatively, 89.8% of Orthofix Medical shares are owned by institutional investors. 65.8% of LENSAR shares are owned by insiders. Comparatively, 2.7% of Orthofix Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Orthofix Medical had 2 more articles in the media than LENSAR. MarketBeat recorded 2 mentions for Orthofix Medical and 0 mentions for LENSAR. Orthofix Medical's average media sentiment score of 0.51 beat LENSAR's score of 0.00 indicating that Orthofix Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
LENSAR	Neutral
Orthofix Medical	Positive

LENSAR presently has a consensus target price of $11.50, indicating a potential upside of 62.66%. Orthofix Medical has a consensus target price of $14.75, indicating a potential upside of 69.35%. Given Orthofix Medical's stronger consensus rating and higher probable upside, analysts clearly believe Orthofix Medical is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Orthofix Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

LENSAR has higher earnings, but lower revenue than Orthofix Medical. LENSAR is trading at a lower price-to-earnings ratio than Orthofix Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.49	-$34.28M	-$0.33	N/A
Orthofix Medical	$822.31M	0.43	-$92.19M	-$1.54	N/A

LENSAR has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Orthofix Medical has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

Summary

Orthofix Medical beats LENSAR on 9 of the 16 factors compared between the two stocks.

How does LENSAR compare to Mobia Medical?

LENSAR (NASDAQ:LNSR) and Mobia Medical (NASDAQ:MOBI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

40.2% of LENSAR shares are held by institutional investors. 65.8% of LENSAR shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Mobia Medical had 4 more articles in the media than LENSAR. MarketBeat recorded 4 mentions for Mobia Medical and 0 mentions for LENSAR. Mobia Medical's average media sentiment score of 1.19 beat LENSAR's score of 0.00 indicating that Mobia Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
LENSAR	Neutral
Mobia Medical	Positive

LENSAR presently has a consensus target price of $11.50, suggesting a potential upside of 62.66%. Mobia Medical has a consensus target price of $20.75, suggesting a potential upside of 96.87%. Given Mobia Medical's stronger consensus rating and higher probable upside, analysts clearly believe Mobia Medical is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Mobia Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

LENSAR has higher revenue and earnings than Mobia Medical. LENSAR is trading at a lower price-to-earnings ratio than Mobia Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.49	-$34.28M	-$0.33	N/A
Mobia Medical	$32.04M	10.95	-$46.50M	-$20.18	N/A

LENSAR has a net margin of 57.57% compared to Mobia Medical's net margin of 0.00%. Mobia Medical's return on equity of 0.00% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	57.57%	-529.08%	50.03%
Mobia Medical	N/A	N/A	N/A

Summary

Mobia Medical beats LENSAR on 8 of the 15 factors compared between the two stocks.

How does LENSAR compare to CapsoVision?

CapsoVision (NASDAQ:CV) and LENSAR (NASDAQ:LNSR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

CapsoVision has a beta of -2.47, suggesting that its share price is 347% less volatile than the broader market. Comparatively, LENSAR has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

CapsoVision has higher earnings, but lower revenue than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	24.75	-$25.32M	-$0.47	N/A
LENSAR	$58.44M	1.49	-$34.28M	-$0.33	N/A

CapsoVision presently has a consensus price target of $9.50, suggesting a potential upside of 41.79%. LENSAR has a consensus price target of $11.50, suggesting a potential upside of 62.66%. Given LENSAR's stronger consensus rating and higher possible upside, analysts plainly believe LENSAR is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

40.2% of LENSAR shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by company insiders. Comparatively, 65.8% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

LENSAR has a net margin of 57.57% compared to CapsoVision's net margin of -214.74%. CapsoVision's return on equity of -177.85% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-214.74%	-177.85%	-135.07%
LENSAR	57.57%	-529.08%	50.03%

In the previous week, CapsoVision had 5 more articles in the media than LENSAR. MarketBeat recorded 5 mentions for CapsoVision and 0 mentions for LENSAR. CapsoVision's average media sentiment score of 1.70 beat LENSAR's score of 0.00 indicating that CapsoVision is being referred to more favorably in the media.

Company	Overall Sentiment
CapsoVision	Very Positive
LENSAR	Neutral

Summary

LENSAR beats CapsoVision on 9 of the 15 factors compared between the two stocks.

How does LENSAR compare to Avita Medical?

LENSAR (NASDAQ:LNSR) and Avita Medical (NASDAQ:RCEL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

LENSAR has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Avita Medical has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market.

40.2% of LENSAR shares are held by institutional investors. Comparatively, 27.7% of Avita Medical shares are held by institutional investors. 65.8% of LENSAR shares are held by company insiders. Comparatively, 2.2% of Avita Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

LENSAR has a net margin of 57.57% compared to Avita Medical's net margin of -56.96%. Avita Medical's return on equity of 0.00% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	57.57%	-529.08%	50.03%
Avita Medical	-56.96%	N/A	-78.53%

LENSAR currently has a consensus price target of $11.50, suggesting a potential upside of 62.66%. Avita Medical has a consensus price target of $11.40, suggesting a potential upside of 3.45%. Given LENSAR's higher probable upside, research analysts plainly believe LENSAR is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Avita Medical had 2 more articles in the media than LENSAR. MarketBeat recorded 2 mentions for Avita Medical and 0 mentions for LENSAR. Avita Medical's average media sentiment score of 0.39 beat LENSAR's score of 0.00 indicating that Avita Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
LENSAR	Neutral
Avita Medical	Neutral

LENSAR has higher earnings, but lower revenue than Avita Medical. LENSAR is trading at a lower price-to-earnings ratio than Avita Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.49	-$34.28M	-$0.33	N/A
Avita Medical	$71.61M	4.74	-$48.59M	-$1.44	N/A

Summary

Avita Medical beats LENSAR on 9 of the 16 factors compared between the two stocks.

Get LENSAR News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNSR vs. The Competition

Export

Metric	LENSAR	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$86.86M	$5.55B	$7.24B	$13.19B
Dividend Yield	N/A	1.80%	2.57%	12.81%
P/E Ratio	-21.42	25.34	275.49	25.40
Price / Sales	1.49	72.49	646.01	89.45
Price / Cash	N/A	32.64	76.25	51.42
Price / Book	-3.24	5.69	10.46	6.33
Net Income	-$34.28M	$151.55M	$3.49B	$358.33M
7 Day Performance	-6.97%	0.66%	0.59%	1.12%
1 Month Performance	-16.23%	-3.33%	-1.74%	-2.39%
1 Year Performance	-42.89%	6.79%	18.13%	5.35%

LENSAR Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNSR LENSAR	2.6668 of 5 stars	$7.07 -0.3%	$11.50 +62.7%	-42.9%	$86.86M	$58.44M	N/A	150	Positive News
OBIO Orchestra BioMed	3.5919 of 5 stars	$6.20 +2.6%	$13.17 +112.4%	+149.2%	$369.38M	$33.48M	N/A	4	Analyst Forecast
OFIX Orthofix Medical	2.7452 of 5 stars	$9.04 -0.6%	$14.75 +63.2%	-40.8%	$366.57M	$822.31M	N/A	1,605
MOBI Mobia Medical	4.4641 of 5 stars	$10.86 +0.8%	$20.75 +91.1%	N/A	$361.53M	$32.04M	N/A	167	Negative News Gap Down
CV CapsoVision	3.5069 of 5 stars	$6.44 +1.0%	$9.50 +47.5%	+41.4%	$322.32M	$13.55M	N/A	99	News Coverage Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNSR) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LENSAR (LNSR) Competitors

LNSR vs. OBIO, OFIX, MOBI, CV, and RCEL

How does LENSAR compare to Orchestra BioMed?

Summary

How does LENSAR compare to Orthofix Medical?

Summary

How does LENSAR compare to Mobia Medical?

Summary

How does LENSAR compare to CapsoVision?

Summary

How does LENSAR compare to Avita Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNSR vs. The Competition

LENSAR Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LENSAR (LNSR) Competitors

LNSR vs. OBIO, OFIX, MOBI, CV, and RCEL

How does LENSAR compare to Orchestra BioMed?

Do analysts recommend LNSR or OBIO?

Which has more volatility & risk, LNSR or OBIO?

Is LNSR or OBIO more profitable?

Which has preferable valuation & earnings, LNSR or OBIO?

Does the media refer more to LNSR or OBIO?

Do institutionals & insiders believe in LNSR or OBIO?

Summary

How does LENSAR compare to Orthofix Medical?

Is LNSR or OFIX more profitable?

Do institutionals and insiders have more ownership in LNSR or OFIX?

Does the media favor LNSR or OFIX?

Do analysts recommend LNSR or OFIX?

Which has stronger earnings & valuation, LNSR or OFIX?

Which has more risk & volatility, LNSR or OFIX?

Summary

How does LENSAR compare to Mobia Medical?

Do insiders & institutionals hold more shares of LNSR or MOBI?

Does the media prefer LNSR or MOBI?

Do analysts recommend LNSR or MOBI?

Which has better earnings & valuation, LNSR or MOBI?

Is LNSR or MOBI more profitable?

Summary

How does LENSAR compare to CapsoVision?

Which has more volatility & risk, CV or LNSR?

Which has stronger earnings & valuation, CV or LNSR?

Do analysts prefer CV or LNSR?

Do insiders & institutionals have more ownership in CV or LNSR?

Is CV or LNSR more profitable?

Does the media refer more to CV or LNSR?

Summary

How does LENSAR compare to Avita Medical?

Which has more risk and volatility, LNSR or RCEL?

Do institutionals & insiders hold more shares of LNSR or RCEL?

Is LNSR or RCEL more profitable?

Do analysts rate LNSR or RCEL?

Does the media prefer LNSR or RCEL?

Which has preferable valuation & earnings, LNSR or RCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNSR vs. The Competition

LENSAR Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools